Credit Suisse Ag Nuvation Bio Inc. Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.26 - $2.1 $7,232 - $12,054	-5,740 Reduced 3.48%	159,157 $213,000
Q2 2023 Aug 11, 2023	BUY	$1.56 - $1.84 $67,716 - $79,870	43,408 Added 35.73%	164,897 $296,000
Q1 2023 May 10, 2023	BUY	$1.6 - $2.48 $8,470 - $13,129	5,294 Added 4.56%	121,489 $201,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $53,193 - $79,157	31,663 Added 37.46%	116,195 $223,000
Q3 2022 Nov 10, 2022	BUY	$0.29 - $4.04 $187 - $2,617	648 Added 0.77%	84,532 $189,000
Q2 2022 Aug 12, 2022	BUY	$3.24 - $5.85 $23,052 - $41,622	7,115 Added 9.27%	83,884 $271,000
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $16,463 - $31,602	3,579 Added 4.89%	76,769 $403,000
Q4 2021 Feb 14, 2022	SELL	$7.75 - $10.05 $102,168 - $132,489	-13,183 Reduced 15.26%	73,190 $621,000
Q3 2021 Nov 12, 2021	BUY	$7.78 - $10.0 $1,556 - $2,000	200 Added 0.23%	86,373 $858,000
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $794,515 - $1.25 Million	86,173 New	86,173 $795,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.